Why the study?
It was unknown whether acarbose could reduce cardiovascular events and new-onset Type 2 diabetes in patients with established coronary heart disease and impaired glucose tolerance.
Does acarbose reduce the frequency of cardiovascular events and incidence of Type 2 diabetes in patients with established coronary heart disease and impaired glucose tolerance?
Does acarbose reduce the frequency of cardiovascular events and incidence of Type 2 diabetes in patients with established coronary heart disease and impaired glucose tolerance?
In patients with coronary heart disease and impaired glucose tolerance, acarbose reduces the risk of new-onset diabetes but does not reduce major adverse cardiovascular events.
Acarbose fails to reduce MACE in CHD with IGT; leaves open diabetes prevention role in this population.
Many studies indicated postprandial hyperglycemia was closely related to the development of diabetes and the risk of cardiovascular disease. Acarbose was shown to delay the onset of diabetes in people with impaired glucose tolerance that was at low cardiovascular risk. The Acarbose Cardiovascular Evaluation (ACE) trial formally evaluated whether acarbose could reduce the frequency of cardiovascular events in patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of Type 2 diabetes could be reduced. The Acarbose Cardiovascular Evaluation trial represented that acarbose did not reduce the risk of Major Adverse Cardiovascular Events (MACE), but the risk of new-onset diabetes by 18% for a median of 5.0 years follow-up.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: